The Next Generation of CJD Detection: How Emerging Biomarker Technologies Are Changing What Newark Neurologists Can See
Traditional neuroimaging has long served as the primary diagnostic anchor for suspected CJD, but a new generation of biomarker-based tests is rapidly redefining what is detectable — and how early. From plasma phosphorylated tau to advanced cerebrospinal fluid assays, these tools are beginning to reach clinical settings in and around Newark, offering families faster, more accurate pathways to diagnosis before irreversible neurological damage accumulates.